Previous 10 | Next 10 |
Natera's (NTRA) revenue and volume growth rate in Q2 2021 was the largest Y/Y growth in its history as a publicly traded company.Total revenues for the Q2 of 2021 are expected to be ~$138-$141M vs. consensus of $127.48M, which represents ~60% Y/Y growth.The Co. expects its product revenu...
Natera Reports Preliminary Second Quarter 2021 Results Record Growth in Revenues and Tests Processed; Women's Health Business Cash Flow Breakeven PR Newswire AUSTIN, Texas , July 19, 2021 /PRNewswire/ -- Natera, Inc. (Nasdaq: NTRA) ("Natera" or the "Comp...
SusanneB/E+ via Getty Images As the third quarter gets underway, BTIG has issued its list of top large-cap stock picks. The picks are the highest-conviction stocks over a 12-month time horizon starting H2 2021. Among sectors, BTIG is overweight three areas: Energy (XLE), Financials (XLF) and ...
New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer Data presented in oral session at the 2021 ESMO GI Congress shows >99% of MRD-negative patients were recurrence-free at 6 months of follow-up...
Natera, Inc. is a leading global diagnostics company developing cell-free DNA ("cfDNA") tests focusing on women's health, oncology, and organ health. Natera's current diagnostics product offering includes ~10 different unique tests with most of the product revenues coming from th...
Natera (NASDAQ: NTRA) has quietly grown its market cap by more than 875% in the past five years, trouncing the 103% gains of the S&P 500 over that time frame. The $10.25 billion med-tech company, which honed its diagnostics craft on non-invasive blood testing to screen for fetal...
Natera ([[NTRA]] +0.4%) and BGI Genomics announces the launch of the BGI/Natera Signatera Assay in China.The company's Signatera assay has been utilized in numerous clinical studies across non-small cell lung, bladder, breast and colorectal cancers, to identify molecular r...
Natera and BGI Genomics Announce Commercial Launch of the BGI/Natera Signatera Assay in China The formal launch of the BGI/Natera Signatera Assay is the next step towards achieving global access to personalized ctDNA testing PR Newswire AUSTIN, Texas and SHENZH...
4 Top Health Care Stocks To Add To Your Watchlist This Week Health care stocks have been in focus in the stock market over the past year for obvious reasons. Everyone was taken aback as we were plagued by the global pandemic. However, every crisis presents a new opportunity. Fun...
Natera Awarded Advanced Diagnostic Laboratory Test (ADLT) Status for its Signatera® MRD Test From CMS PR Newswire AUSTIN, Texas , June 18, 2021 /PRNewswire/ -- Natera,Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, today an...
News, Short Squeeze, Breakout and More Instantly...
Study reports high accuracy of Signatera for surveillance of MCC patients, suggests potential to reduce frequency of surveillance imaging Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced a new study published in the Journal of Clinical Oncolog...
2024-07-23 12:58:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-13 10:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...